Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations

A critical step to evaluate the potential in vivo antiviral activity of a drug is to connect the in vivo exposure to its in vitro antiviral activity. The Anti–SARS‐CoV‐2 Repurposing Drug Database is a database that includes both in vitro anti–SARS‐CoV‐2 activity and in vivo pharmacokinetic data to f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinyuan, Yang, Yuching, Grimstein, Manuela, Liu, Guansheng, Kitabi, Eliford, Fan, Jianghong, Wang, Ying‐Hong, Earp, Justin, Weaver, James L., Zhu, Hao, Liu, Jiang, Reynolds, Kellie S., Huang, Shiew‐Mei, Wang, Yaning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420371/
https://www.ncbi.nlm.nih.gov/pubmed/34218521
http://dx.doi.org/10.1002/psp4.12681
_version_ 1783748908773539840
author Zhang, Xinyuan
Yang, Yuching
Grimstein, Manuela
Liu, Guansheng
Kitabi, Eliford
Fan, Jianghong
Wang, Ying‐Hong
Earp, Justin
Weaver, James L.
Zhu, Hao
Liu, Jiang
Reynolds, Kellie S.
Huang, Shiew‐Mei
Wang, Yaning
author_facet Zhang, Xinyuan
Yang, Yuching
Grimstein, Manuela
Liu, Guansheng
Kitabi, Eliford
Fan, Jianghong
Wang, Ying‐Hong
Earp, Justin
Weaver, James L.
Zhu, Hao
Liu, Jiang
Reynolds, Kellie S.
Huang, Shiew‐Mei
Wang, Yaning
author_sort Zhang, Xinyuan
collection PubMed
description A critical step to evaluate the potential in vivo antiviral activity of a drug is to connect the in vivo exposure to its in vitro antiviral activity. The Anti–SARS‐CoV‐2 Repurposing Drug Database is a database that includes both in vitro anti–SARS‐CoV‐2 activity and in vivo pharmacokinetic data to facilitate the extrapolation from in vitro antiviral activity to potential in vivo antiviral activity for a large set of drugs/compounds. In addition to serving as a data source for in vitro anti–SARS‐CoV‐2 activity and in vivo pharmacokinetic information, the database is also a calculation tool that can be used to compare the in vitro antiviral activity with in vivo drug exposure to identify potential anti–SARS‐CoV‐2 drugs. Continuous development and expansion are feasible with the public availability of this database.
format Online
Article
Text
id pubmed-8420371
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84203712021-09-07 Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations Zhang, Xinyuan Yang, Yuching Grimstein, Manuela Liu, Guansheng Kitabi, Eliford Fan, Jianghong Wang, Ying‐Hong Earp, Justin Weaver, James L. Zhu, Hao Liu, Jiang Reynolds, Kellie S. Huang, Shiew‐Mei Wang, Yaning CPT Pharmacometrics Syst Pharmacol Reviews A critical step to evaluate the potential in vivo antiviral activity of a drug is to connect the in vivo exposure to its in vitro antiviral activity. The Anti–SARS‐CoV‐2 Repurposing Drug Database is a database that includes both in vitro anti–SARS‐CoV‐2 activity and in vivo pharmacokinetic data to facilitate the extrapolation from in vitro antiviral activity to potential in vivo antiviral activity for a large set of drugs/compounds. In addition to serving as a data source for in vitro anti–SARS‐CoV‐2 activity and in vivo pharmacokinetic information, the database is also a calculation tool that can be used to compare the in vitro antiviral activity with in vivo drug exposure to identify potential anti–SARS‐CoV‐2 drugs. Continuous development and expansion are feasible with the public availability of this database. John Wiley and Sons Inc. 2021-08-01 2021-09 /pmc/articles/PMC8420371/ /pubmed/34218521 http://dx.doi.org/10.1002/psp4.12681 Text en Published 2021. This article is a U.S. Government work and is in the public domain in the USA. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Zhang, Xinyuan
Yang, Yuching
Grimstein, Manuela
Liu, Guansheng
Kitabi, Eliford
Fan, Jianghong
Wang, Ying‐Hong
Earp, Justin
Weaver, James L.
Zhu, Hao
Liu, Jiang
Reynolds, Kellie S.
Huang, Shiew‐Mei
Wang, Yaning
Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
title Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
title_full Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
title_fullStr Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
title_full_unstemmed Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
title_short Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
title_sort anti–sars‐cov‐2 repurposing drug database: clinical pharmacology considerations
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420371/
https://www.ncbi.nlm.nih.gov/pubmed/34218521
http://dx.doi.org/10.1002/psp4.12681
work_keys_str_mv AT zhangxinyuan antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT yangyuching antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT grimsteinmanuela antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT liuguansheng antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT kitabieliford antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT fanjianghong antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT wangyinghong antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT earpjustin antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT weaverjamesl antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT zhuhao antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT liujiang antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT reynoldskellies antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT huangshiewmei antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations
AT wangyaning antisarscov2repurposingdrugdatabaseclinicalpharmacologyconsiderations

Ejemplares similares